Dermatology Times, November 2025 (Vol. 46. No. 11)

Learn more about the in-depth topics covered in the November 2025 print issue of Dermatology Times.

Discover 5 effective tax-saving strategies for investors in dermatology, enhancing portfolio management and planning for 2026 with OJM Group's expert insights.

Maui Derm NP+PA Fall 2025 conference showcases cutting-edge insights in dermatology, featuring expert discussions on skin cancer, atopic dermatitis, and rare dermatoses.

New research reveals ritlecitinib's potential to reverse scarring alopecias by targeting inflammation, offering hope for hair regrowth in autoimmune disorders.

Explore how skin aging and cellular senescence impact overall health, revealing insights into anti-aging strategies and cosmetic conundrums.

Denifanstat emerges as a groundbreaking oral therapy for acne, targeting sebum production and inflammation, promising safer, effective treatment options.

Experts discuss essential skin care strategies for sensitive skin, emphasizing evidence-based cleansing and moisturizing to restore the compromised skin barrier.

Experts discuss effective strategies for managing facial hyperpigmentation, emphasizing personalized treatment plans and the importance of sun protection.

Experts discuss icotrokinra's potential to revolutionize psoriasis treatment with oral therapies, emphasizing efficacy, safety, and patient-centered care at EADV 2025.

ORKA-001 by Oruka Therapeutics offers promising yearly dosing for psoriasis, showcasing extended efficacy and safety in early clinical trials.

Skin pain in atopic dermatitis significantly impacts quality of life, necessitating its recognition and treatment as a vital symptom for better patient outcomes.

Explore the latest FDA approvals in dermatology, including treatments for eczema and psoriasis, and gain insights on chronic spontaneous urticaria.

Mark Kaufmann, MD, discusses how patient realities shape psoriasis treatment choices.

During a Case-Based Roundtable event, Naiem Issa, MD, PhD, guided colleagues through 3 complex atopic dermatitis cases, highlighting how modern topicals can deliver rapid and durable control across age groups.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, discusses Apex Skin’s mission to make research more representative and accessible through integrated, multisite dermatology practices.

Fewer than 20% of eligible patients currently receive injectable therapies, highlighting the need for oral alternatives.

Bambusa Therapeutics reveals promising phase I trial results for BBT001, targeting atopic dermatitis with dual-action bispecific antibodies.

Based on the diagnosis and treatment challenges of CSU, it’s crucial for allergists and dermatologists to work together toward an effective approach based on the latest evidence.